Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080080 · ClinicalTrials.gov registry record · Phase 2
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Point Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00080080: Completed Phase 2 study, sponsored by Point Therapeutics.
NCT00080080 is a Phase 2 study that has completed, run by Point Therapeutics. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00080080, a Phase 2 study, has completed, sponsored by Point Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine the antitumor activity (response rate, time to tumor progression, survival) and safety of docetaxel in combination with talabostat in patients with advanced non-small cell lung cancer (NSCLC) who have failed a prior platinum-containing regimen.
Interventions
- DRUG Docetaxel
- DRUG talabostat (PT-100) tablets
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00080080 record still lists
NCT00080080 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00080080 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00080080 about?
NCT00080080 is a clinical study titled "Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer". The purpose of this study is to determine the antitumor activity (response rate, time to tumor progression, survival) and safety of docetaxel in combination with talabostat in patients with advanced non-small cell lung cancer (NSCLC) who have failed a prior platinum-containing regimen.
What is the current status of trial NCT00080080?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00080080?
The interventions under investigation include: Docetaxel (DRUG), talabostat (PT-100) tablets (DRUG).
Who is sponsoring clinical trial NCT00080080?
This trial is sponsored by Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.